Gabapentin 300/600/800 mg — $0 with Membership

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Nerve Pain from Shingles (Post-Herpetic Neuralgia)

• Pregabalin
• Pregabalin 75/150/300 mg

What Gabapentin 300/600/800 mg is approved for (FDA label)

NEURONTIN ® is indicated for: • Management of postherpetic neuralgia in adults • Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy NEURONTIN is indicated for: • Postherpetic neuralgia in adults ( 1 ) • Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: May 12, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Gabapentin 300/600/800 mg (FDA label)

Capsules • 100 mg: white hard gelatin capsules printed with “VLE” on the body and “Neurontin/100 mg” on the cap • 300 mg: yellow hard gelatin capsules printed with “VLE” on the body and “Neurontin/300 mg” on the cap • 400 mg: orange hard gelatin capsules printed with “VLE” on the body and “Neurontin/400 mg” on the cap Tablets • 600 mg: white elliptical film-coated scored tablets debossed with “NT” and “16” on one side • 800 mg: white elliptical film-coated scored tablets debossed with “NT” and “26” on one side Oral solution • 250 mg per 5 mL (50 mg per mL), clear colorless to slightly yellow solution • Capsules: 100 mg, 300 mg, and 400 mg ( 3 ) • Tablets: 600 mg, and 800 mg ( 3 ) • Oral Solution: 250 mg/5mL ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 97935fd9-1d4a-43b6-a5d9-de994591187b. SPL document ID: 2d43f32d-2d96-4011-84ac-507c3307dc27. Label effective date: May 12, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Gabapentin 300/600/800 mg (FDA label)

The following serious adverse reactions are discussed in greater detail in other sections: • Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity [see Warnings and Precautions (5.1) ] • Anaphylaxis and Angioedema [see Warnings and Precautions (5.2) ] • Somnolence/Sedation and Dizziness [see Warnings and Precautions (5.4) ] • Suicidal Behavior and Ideation [see Warnings and Precautions (5.5) ] • Increased Risk of Seizures and Other Adverse Reactions with Abrupt or Rapid Discontinuation [see Warnings and Precautions (5.6) ] • Status Epilepticus [see Warnings and Precautions (5.7) ] • Respiratory Depression [see Warnings and Precautions (5.8) ] • Neuropsychiatric Adverse Reactions (Pediatric Patients 3 to 12 Years of Age) [see Warnings and Precautions (5.9) ] Most common adverse reactions (incidence ≥8% and at least twice that for placebo) were: • Postherpetic neuralgia: Dizziness, somnolence, and peripheral edema ( 6.1 ) • Epilepsy in patients >12 years of age: Somnolence, dizziness, ataxia, fatigue, and nystagmus ( 6.1 ) • Epilepsy in patients 3 to 12 years of age: Viral infection, fever, nausea and/or vomiting, somnolence, and hostility ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Viatris at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 97935fd9-1d4a-43b6-a5d9-de994591187b. SPL document ID: 2d43f32d-2d96-4011-84ac-507c3307dc27. Label effective date: May 12, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Gabapentin 300/600/800 mg (FDA label)

NEURONTIN is contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients. Known hypersensitivity to gabapentin or its ingredients ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 97935fd9-1d4a-43b6-a5d9-de994591187b. SPL document ID: 2d43f32d-2d96-4011-84ac-507c3307dc27. Label effective date: May 12, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Gabapentin 300/600/800 mg (FDA label)

• Drug Reaction with Eosinophilia and Systemic Symptoms (Multiorgan hypersensitivity): Discontinue if alternative etiology is not established ( 5.1 ) • Anaphylaxis and Angioedema: Discontinue and evaluate patient immediately ( 5.2 ) • Driving Impairment; Somnolence/Sedation and Dizziness: Warn patients not to drive until they have gained sufficient experience to assess whether their ability to drive or operate heavy machinery will be impaired ( 5.3 , 5.4 ) • Suicidal Behavior and Ideation: Monitor for suicidal thoughts/behavior ( 5.5 ) • Abrupt or rapid discontinuation may increase the risk for seizures. Withdrawal symptoms, or suicidal behavior and ideation have been observed after discontinuation ( 5.6 ) • Respiratory Depression: May occur with NEURONTIN when used with concomitant central nervous system (CNS) depressants, including opioids, or in the setting of underlying respiratory impairment.

Source: FDA prescribing information (DailyMed). Set ID: 97935fd9-1d4a-43b6-a5d9-de994591187b. SPL document ID: 2d43f32d-2d96-4011-84ac-507c3307dc27. Label effective date: May 12, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Gabapentin 300/600/800 mg (FDA label)

Concentrations increased by morphine; may need dose adjustment ( 5.4 , 7.1 ) 7.1 Opioids Respiratory depression and sedation, sometimes resulting in death, have been reported following coadministration of gabapentin with opioids (e.g., morphine, hydrocodone, oxycodone, buprenorphine) [see Warnings and Precautions (5.8) ] . Hydrocodone Coadministration of NEURONTIN with hydrocodone decreases hydrocodone exposure [see Clinical Pharmacology (12.3) ] . The potential for alteration in hydrocodone exposure and effect should be considered when NEURONTIN is started or discontinued in a patient taking hydrocodone.

Source: FDA prescribing information (DailyMed). Set ID: 97935fd9-1d4a-43b6-a5d9-de994591187b. SPL document ID: 2d43f32d-2d96-4011-84ac-507c3307dc27. Label effective date: May 12, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.